Using MRD negativity to measure depth of response \u0026 to discontinue treatment in multiple myeloma

(2:5)

Using MRD after autoSCT as a benchmark for consolidation strategies in myeloma

(2:3)

Using MRD to accelerate drug approval in multiple myeloma

(1:14)

Using MRD to improve patient outcomes

(2:7)

Using MRD Status as an Endpoint for Drug Approval with Dr. Manni Mohyuddin

(1:1:42)

Using MRD to guide therapy in multiple myeloma

(1:38)

The importance of using MRD to guide treatment decisions in ALL

(1:5)

Using MRD to guide MM treatment

(1:34)

🔴 LIVE 🏆85000 PUSH + 1v1 WITH SUBSCRIBERS

(1:55:6)

Using MRD as an endpoint in clinical trials

(1:38)

Using MRD to improve prognostication during the maintenance phase of myeloma treatment

(1:25)

Minimal residual disease (MRD) in CLL: Is it clinically relevant?

(21:9)

Using MRD to identify which patients with AML will benefit the most from transplantation

(1:4)

Using MRD to guide treatment decisions in myeloma

(1:15)

Minimal Residual Disease (MRD) | High Impact Topic (HIT)

(4:44)

Using MRD to guide treatment decisions during SCT in multiple myeloma

(2:55)

Using MRD to guide treatment decisions in the clinic

(1:27)

Approaching MRD in Multiple Myeloma

(23:32)

A Practical Approach to MRD: Testing with clonoSEQ

(1:12:5)

Approaches to and the use of MRD in ALL

(5:17)